Zinc Sulfate Unspecified Form
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
- Zinc Sulfate Unspecified Form
- Zinc Sulfate: From an Unspecified Original Indication to Severe Nonproliferative Diabetic Retinopathy
Zinc Sulfate: From an Unspecified Original Indication to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Zinc sulfate is an injectable zinc product. The US approval record compiled for this report does not state an approved indication, and the only authorization on file is cancelled. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy. Currently there are 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the available data |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| US Market Status | Cancelled only |
| Number of NDAs | 1 (ANDA218059, cancelled) |
| Recommended Decision | Hold |
Other predicted indications, all at evidence level L5 and Hold:
| Rank | Predicted Indication | TxGNN Score |
|---|---|---|
| 2 | Diabetic retinopathy | 99.76% |
| 3 | Bronchitis | 99.61% |
| 4 | Diabetic cataract | 99.35% |
| 5 | Dermatitis | 99.15% |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this entry, and the approved indication text is blank in the regulatory data. The following rationale is therefore a plausible but unverified hypothesis, not an established finding.
Zinc is a cofactor for antioxidant enzymes such as Cu/Zn superoxide dismutase. Oxidative stress and inflammation contribute to the development of diabetic retinopathy, so zinc-dependent antioxidant defense could plausibly relate to the disease. The relationship between the original indication and the new one cannot be assessed, because no original indication is recorded.
The same reasoning applies to the closely related predictions. Diabetic cataract may involve lens oxidative damage in hyperglycemia. Dermatitis may involve zinc’s roles in skin barrier function and anti-inflammatory signaling. Bronchitis may involve zinc’s role in immune function and epithelial integrity. None of these links has trial or literature support in the data compiled for this report.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA218059 (cancelled) | Zinc Sulfate (Apotex Corp) | Injection | Not stated |
Safety Considerations
Please refer to the package insert for safety information. No warnings, contraindications, or drug interaction records were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score (99.84%) but no clinical trials or publications behind it, so the evidence level is L5. The only US authorization is cancelled, and safety information and mechanism of action are both missing.
To proceed, the following is needed:
- A systematic literature and trial registry search for zinc in diabetic retinopathy and the other predicted indications
- Mechanism of action data, for example from DrugBank
- FDA package insert warnings and contraindications, which are required before any safety screening
- Confirmation of the original approved indication and the reason for the cancelled authorization
- A route and formulation compatibility assessment, since the only known product is an injection and ocular use would likely need a different route
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.